You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Klebsiella pneumoniae is an encapsulated human pathogen capable of causing a myriad of human infections. Recently, K. pneumoniae has also emerged as one the most common causes of secondary bacterial pneumonia in COVID-19 patients. Over the last 40 years, K. pneumoniae has evolved into two distinct pathotypes, known as classical K. pneumoniae (cKp) and hypervirulent K. pneumoniae (h ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Targeting the P Selectin Pathway to Improve ARDS Survival
SBC: AQUALUNG THERAPEUTICS, CORP Topic: NHLBIABSTRACT Acute respiratory distress syndrome (ARDS) is a critical illness with 30- 40% mortality and currently there are no FDA-approved therapies. Quell Pharma and Aqualung Therapeutics have developed a recombinant soluble, cell-free form of recombinant human P-selectin glycoprotein ligand-1 (PSGL-1) designated Tandem P-Selectin glycoprotein ligand-1 immunoglobulin (TSGL-Ig), which is a potent pa ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of lysosome targeted therapeutics
SBC: MAJESTIC THERAPEUTICS, LLC Topic: 102Project Summary/Abstract Lysosomal proteolysis facilitates the turnover of organelles and selected long-lived proteins and is a critical regulator of cellular homeostasis. Its aberrant activation promotes drug resistance and cancer progression by generating alternative sources of survival sustaining metabolic fuel to cells that are stressed by hypoxia, radiation, chemotherapy, and targeted agents. ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of a Pre-Exposure Vaccine for Population-Level ProtectionAgainst Staphylococcus aureus Infection
SBC: FORWARD DEFENSE, LLC Topic: NIAIDPROJECT SUMMARY Staphylococcus aureus is an aggressive antibiotic-resistant human bacterial pathogen. S. aureus is a leading cause of infectious disease morbidity, mortality, and hospital-associated infection in the U.S., and a formidable health threat worldwide. Given the rapid acquisition of drug resistance by S. aureus, universal vaccination has been a premier goal in the field to provide a dur ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Klebsiella pneumoniae is a leading cause of healthcare- and community-associated infections. Moreover, K. pneumoniae is frequently resistant to last line antibiotics like third generation cephalosporins and carbapenems. In fact, carbapenem-resistant Klebsiella is considered an Urgent Threat by the CDC requiring aggressive, immediate action. One of the five core actions proposed by ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension
SBC: AQUALUNG THERAPEUTICS, CORP Topic: NHLBIABSTRACT Pulmonary arterial hypertension (PAH) is a fatal disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A1 R42 Fast Track STTR application focuses on eNAMPT (extra- cellular nicotinamide phosphoribosyltransferase) as a novel, highly attractive PAH target. Aqualung Therapeutics has developed a humanized eNAMPT-neutralizing mAb, ALT-10 ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Wearable modular high-density diffuse optical tomography
SBC: EsperImage LLC Topic: 103Project Summary: EsperImage, a startup company out of Washington University (WUSTL), will develop high fidelity, wearable, optical technology that transcends limitations of both previous optical neuroimaging and magnetic resonance imaging (MRI) tools to provide naturalistic brain imaging in adults and children. A neurodevelopmental disorder affecting 1/54 children in the general population, autism ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Developing a clinical diagnostic tool for age-related cochlear synaptopathy.
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIAAge-related hearing loss (ARHL) is the predominant neurodegenerative disease of aging. Recent animal studies have demonstrated that the earliest cochlear pathology due to noise and aging involves a loss of the inner hair cell ribbon synapse. The early consequences of this synaptic loss are not believed to affect hearing sensitivity, but rather, impair speech understanding in background noise. Whil ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome
SBC: ILUMINOS THERAPEUTICS LLC Topic: 106Project Summary Down syndrome (DS) is caused by human chromosome 21 trisomy (hsa21) and is the most common genetic form of intellectual and cognitive disability, occurring in ~1 in 700 live births. DS patients also exhibit age-related progressive cognitive decline, neurodegeneration, and the development of Alzheimerandapos;s disease (AD)-like pathology by 40-50 years of age. There are currently no ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity
SBC: AQUALUNG THERAPEUTICS, CORP Topic: 300ABSTRACT Inflammatory bowel disease (IBD) is a debilitating disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A0 R42 STTR application focuses on a highly novel humanized monoclonal antibody (mAb), ALT-100, to target and neutralize eNAMPT (extracellular nicotinamide phosphoribosyltransferase), a damage-associated molecular pattern protein ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health